Cancer Res Treat.  2004 Apr;36(2):91-92.

Oxaliplatin: Is It a New Standard Weapon for Colorectal Cancer?

• Kim SY

Abstract

No abstract available.

MeSH Terms

Colorectal Neoplasms*

Reference

1. Kwon HC, Kim KT, Lee SA, Park JS, Kim SH, Kim JS, Kim HJ. Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX4) as first-line therapy for patients with metastatic colorectal cancer. Cancer Res Treat. 2004; 36:115–120.

2. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16:301–308. PMID: 9440757.

3. Advanced colorectal cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992; 10:896–903. PMID: 1534121.

4. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998; 9:1053–1071. PMID: 9834817.

5. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996; 7:95–98. PMID: 9081400.

6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938–2947. PMID: 10944126.

7. Haller D, Catalano P, Macdonald J. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol. 1998; 17:256a. (abst).

8. Ducreaux M, Bouche O, Pignon JP, Raoul JL, Mousseau M, Deguiral P, Berger C, Cassan P, Leduc B, Bedenne L. Randomized trial comparing three different schedules of infusional 5FU and raltitrexed alone in first line metastatic colorectal cancer. Final results of th Federation francophone de Cancerologie Digestive 9601 trial. Ann Oncol. 2002; 13(suppl5):71. (abstr 259).

9. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. The Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343:905–914. PMID: 11006366.

10. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000; 355:1041–1047. PMID: 10744089.

11. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23–30. PMID: 14665611.